Immatics Past Earnings Performance
Past criteria checks 0/6
Immatics has been growing earnings at an average annual rate of 11.9%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 37.9% per year.
Key information
11.9%
Earnings growth rate
24.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 37.9% |
| Return on equity | -43.1% |
| Net Margin | -179.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely
Sep 26
We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely
Jun 12Immatics launches $110M stock offering
Oct 10Cancer immunotherapy biotech Immatics up 18% on 4x normal volume
Jul 19Here's Why We're Watching Immatics' (NASDAQ:IMTX) Cash Burn Situation
Jan 29Analysts' Revenue Estimates For Immatics N.V. (NASDAQ:IMTX) Are Surging Higher
Dec 16Immatics N.V. (NASDAQ:IMTX) Analysts Are Pretty Bullish On The Stock After Recent Results
Apr 01What Is The Ownership Structure Like For Immatics N.V. (NASDAQ:IMTX)?
Jan 18Immatics reports Q3 results
Dec 02Immatics (IMTX) Investor Presentation - Slideshow
Nov 13Revenue & Expenses BreakdownBeta
How Immatics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 54 | -97 | 38 | 0 |
| 30 Sep 23 | 76 | -84 | 38 | 0 |
| 30 Jun 23 | 85 | -79 | 37 | 0 |
| 31 Mar 23 | 80 | -68 | 36 | 0 |
| 31 Dec 22 | 173 | 38 | 36 | 0 |
| 30 Sep 22 | 151 | 34 | 35 | 0 |
| 30 Jun 22 | 142 | 28 | 35 | 0 |
| 31 Mar 22 | 130 | 15 | 35 | 0 |
| 31 Dec 21 | 35 | -93 | 34 | 0 |
| 30 Sep 21 | 28 | -95 | 34 | 0 |
| 30 Jun 21 | 30 | -231 | 35 | 0 |
| 31 Mar 21 | 32 | -226 | 36 | 0 |
| 31 Dec 20 | 31 | -211 | 34 | 0 |
| 30 Sep 20 | 26 | -208 | 30 | 0 |
| 30 Jun 20 | 23 | -49 | 24 | 0 |
| 31 Mar 20 | 22 | -34 | 16 | 0 |
| 31 Dec 19 | 18 | -32 | 12 | 0 |
| 31 Dec 18 | 4 | -31 | 8 | 0 |
Quality Earnings: IMTX is currently unprofitable.
Growing Profit Margin: IMTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IMTX is unprofitable, but has reduced losses over the past 5 years at a rate of 11.9% per year.
Accelerating Growth: Unable to compare IMTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IMTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: IMTX has a negative Return on Equity (-43.09%), as it is currently unprofitable.